Eleftheria Kranidioti, Isis Ricaño-Ponce, Nikolaos Antonakos , Evdoxia Kyriazopoulou, Antigone Kotsaki, Iraklis Tsangaris, Dimitra Markopoulou, Nikoleta Rovina, Eleni Antoniadou, Ioannis Koutsodimitropoulos, George N Dalekos, Glykeria Vlachogianni, Karolina Akinosoglou, Vasilios Koulouras, Apostolos Komnos, Theano Kontopoulou, George Dimopoulos, Mihai G Netea , Vinod Kumar, Evangelos J. Giamarellos-Bourboulis

Critical Care Medicine 2024 Aug 23 Epub ahead of print
DOI: 10.1097/CCM.0000000000006391View article 🡆

Funding

Dr. Dalekos is an advisor or lecturer for Pfizer, Roche, Sanofi, and Sobi and he received research grants from Gilead and has served as principal investigator in studies for Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics Inc, Tiziana Life Sciences, Bayer, Astellas, Pfizer, Amyndas Pharmaceuticals, CymaBay Therapeutics Inc., Sobi, and Intercept Pharmaceuticals. Dr. Netea is supported by an European Research Council Advanced Grant (number 833247) and a Spinoza grant from the Netherlands Organization for Scientific Research. He is a scientific founder of TTxD, Lemba, and Biotrip and he has received independent educational grants from TTxD, GSK, Ono Pharma, and ViiV Healthcare. Dr. Giamarellos-Bourboulis has received honoraria from Abbott Products Operations, bioMérieux, ThermoFisherBrahms GmbH, GSK, InflaRx GmbH, Sobi, and XBiotech Inc; independent educational grants from Abbott Products Operations, AbbVie, bioMérieux Inc, Johnson & Johnson, MSD, Novartis, Sobi, and UCB; and funding from the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), the Horizon 2020 European Grants ImmunoSep and RISCinCOVID (granted to the Hellenic Institute for the Study of Sepsis), and the Horizon Health European Grant EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis). Dr. Kranidioti’s institutions received funding from The Hellenic Institute for the Study of Sepsis, bioMerieux, and Spinoza grant of the Netherlands Organization for Scientific Research. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Keywords: MALS; Immune activation; Metabolites;

Related Study: PROVIDE